Skip to main content
Clinical Trials/ACTRN12618000658213
ACTRN12618000658213CompletedPhase 1

Dexmedetomidine for delirium at the end of life: an open-label single arm study with dose escalation for terminal delirium in patients admitted to an inpatient palliative care unit

Illawarra Shoalhaven Local Health District0 sites22 target enrollmentStarted: April 24, 2018Last updated:

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
22

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • Admitted to the Port Kembla Palliative Care Unit at Illawarra Shoalhaven Local Health District
  • English Speaking
  • Develop a terminal delirium during admission
  • End of life

Exclusion Criteria

  • Non English speaking
  • Severe left ventricular dysfunction of <20% EF
  • Severe renal failure of eGFR of 30 or less
  • Severe hepatic failure with MELD score of 30 or greater
  • Bradycardia with restring heart rate of <65 BPM on screening

Investigators

Similar Trials